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year or $49.0M/year nationally. ConClusions: Differences in study design should 
be addressed when conducting an ITC. The evidence from this ITC shows that abira-
terone and enzalutamide have similar efficacy in OS in mCRPC post chemotherapy. 
However, abiraterone is cost saving compared to enzalutamide in this analysis.
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objeCtives: Information about acute myeloid leukaemia (AML), including the 
costs of treatment and survival-estimates, are usually derived from clinical trial 
data. However, it is not known whether this information is generalizable to non-
trial patients. This study was carried out to evaluate the differences in medical costs 
and survival between trial and non-trial patients with AML; and hence assess the 
external validity of trial data to the general patient population. Methods: The 
Haematological Malignancy Research Network (HMRN, www.hmrn.org) is an estab-
lished population-based patient cohort that registers around 2000 newly diagnosed 
patients each year. All adults (≥ 18) newly diagnosed with AML between September 
2004 and August 2007 and treated with induction intent were included. Patients were 
followed until August 2012, and the comparative outcomes were medical costs and 
survival. Standard statistical analyses were used to measure unadjusted difference 
in outcomes, and propensity score analyses were applied to measure differences by 
adjusting for baseline imbalance in pre-treatment characteristics between trial and 
non-trial patients. Results: Overall, 173 patients treated with induction intent were 
included, of which 106 were trial and 67 non-trial. Trial participation was associated 
with younger age, fewer comorbidities, better prognosis, and being treated at teach-
ing hospitals. Before controlling for patients’ characteristics, trial patients had better 
survival and incurred higher costs (p< .0001 for both). After controlling for patients’ 
characteristics by carrying out propensity score analyses, these differences remained 
significant in both survival (median survival 28.7 vs. 8 months; p< .0001) and medical 
costs (mean costs £84,497 vs. £49,624; p< .0001). ConClusions: For AML patients 
treated with induction intent, significant differences were observed in treatment costs 
and survival according to trial status, both before and after controlling for patients’ 
pre-treatment characteristics. Data generated solely from clinical trials may therefore 
not be generalizable to non-trial patients and should be treated with some caution 
when used to facilitate decision-making.
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objeCtives: To review the data available on excision margins following breast-
conserving therapy (BCT), focusing on definitions of positive and clear margins, per-
centage of operations resulting in positive margins, the effect of positive margins on 
future treatment, and the relationship between positive margins and disease-free 
and overall survival. Methods: Targeted searches of PubMed were conducted using 
a predefined search strategy. Data from robust systematic reviews and/or meta-anal-
yses were given priority. Results: Definitions of positive and negative margins are 
variable, but typically a clear margin of 2 mm is considered acceptable. Most studies 
indicate positive margins in 20%-40% of patients after wide local excision. Guidelines 
recommend that patients with positive margins after BCT undergo repeat surgery, 
and in surveys, most physicians said they would recommend re-excision when there 
is tumour within 1 mm of the margin. In the identified studies, 20%-30% of patients 
underwent re-excision and approximately 2% had multiple re-excisions (two or more); 
10%-15% of patients who initially had lumpectomy later had a mastectomy. There 
is a significant association between margin status and local recurrence (in a recent 
meta-analysis, the odds ratio was 2.42 for positive vs. negative margin status; 95% 
confidence interval, 1.94-3.02; P< 0.001). However, among patients with a clear margin, 
width is not clearly related to risk of local recurrence. Four studies that assessed the 
effect of margin status on overall or disease-specific survival were identified, three 
reported a significant association (e.g., cause-specific survival at 12 years significantly 
associated with margin status, P< 0.001). ConClusions: Definition of adequate mar-
gins remains controversial. None-the-less, final margin status is a key prognostic 
factor following BCT. The data identified suggest that an intervention that reduces 
the rates of positive margins during BCT may have the potential to improve outcomes 
and reduce the burden on patients and health care providers.
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objeCtives: This research was conducted during a review of the manufacturer’s 
submission (MS) to the NICE Single Technology Appraisal programme for beva-
cizumab, a vascular endothelial growth factor (VEGF) inhibitor. Bevacizumab in 
combination with gemcitabine/carboplatin has recently been licensed for use in 
patients with platinum-sensitive or partially platinum-sensitive recurrent advanced 
ovarian cancer. This research compared this new triple therapy with treatments 
used in clinical practice in the UK: platinum monotherapy, gemcitabine/carboplatin, 
paclitaxel/carboplatin, pegylated liposomal doxorubicin hydrochloride (PLDH)/car-
boplatin. Methods: Randomised controlled trials (RCTs) for inclusion were identi-
fied using the MS for bevacizumab. RCTs were assessed for comparability based on 
patient population, disease severity, platinum sensitivity, and treatments received. 
An MTC was conducted using a Bayesian Markov chain Monte Carlo simulation. 
or 500mg. The indirect analysis did not show a statistically significant difference in 
OS between everolimus compared with fulvestrant.
PCN12
sMall MoleCule targeteD theraPies for the seCoND liNe treatMeNt 
of MetastatiC reNal Cell CarCiNoMa (MrCC): a systeMatiC review 
aND iNDireCt CoMParisoN of safety aND effiCaCy
Dranitsaris G.1, Schmitz S.2, Broom R.J.3
1University of Ioannina, Ioannina, Greece, 2Trinity College, Dublin, Ireland, 3Auckland City 
Hospital, Auckland, New Zealand
objeCtives: Patients with mRCC and a good performance status typically receive 
an anti-VEGFR TKI (sunitinib or pazopanib) as initial therapy. Upon disease progres-
sion or intolerance, there are four orally-administered agents approved in the 2nd 
- line setting (including cytokine-refractory). However, head to head comparative 
trial data are limited. In the absence of such data, mixed treatment comparison 
(MTC) models are a widely accepted statistical method for generating comparative 
effectiveness information. In this study, an indirect comparison on the safety and 
efficacy was undertaken between axitinib, sorafenib, pazopanib and everolimus 
for 2nd - line therapy in advanced RCC. Methods: A systematic review of major 
databases was conducted from January 2005 to June 2013 for randomized controlled 
trials evaluating at least one of the four agents in 2nd- line mRCC. Bayesian MTC 
models were fitted to assess comparative effectiveness based on multiple endpoints: 
tumour response, progression free survival (PFS), grade III/IV toxicities such as diar-
rhea, fatigue, hand foot skin reaction, rash and stomatitis as well as treatment 
discontinuations. Results: A total of four randomized trials meeting the inclusion 
criteria were appropriate for the statistical pooling exercise. All four agents seem 
able to induce tumour shrinkage and provide patients with a clinically meaningful 
PFS benefit. Axitinib was superior to pazopanib (HR = 0.64; 95%Crl: 0.42 to 0.96) and 
sorafenib (HR = 0.70; 95%Crl: 0.57 to 0.87) in terms of PFS. However, patients receiv-
ing axitinib would be at an elevated risk for fatigue and to a lesser extent, stoma-
titis. ConClusions: Keeping in the mind the caveats associated with cross-trial 
comparisons, axitinib appears to provide superior PFS benefits relative to pazopanib 
and sorafenib. However, this is at a cost of a higher frequency of some dose-limiting 
toxicities. Everolimus, an mTor inhibitor, is mechanistically distinct from the other 
agents evaluated and would be a useful option post anti-VEGFR TKI failure.
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objeCtives: To perform a systematic review and meta-analysis of all randomized 
controlled trials comparing the efficacy of targeted therapy to conventional CT in 
patients with metastatic Triple-Negative Breast Cancer (TNBC). Methods: Several 
databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The 
primary endpoint was progression-free survival (PFS). We performed a meta-analysis 
(MA) of the published data. The results were expressed as Hazard Ratio (HR) or Risk 
Ratio (RR), with their corresponding 95% confidence intervals (CI 95%). Results: 
The final analysis included 12 trials comprising 2,054 patients with TNBC. It was 
evidenced studies with conventional CT plus targeted therapy including bevacizumab 
(Bev), sorafenib (Sor), cetuximab and iniparib. The PFS was higher in patients who 
received Bev plus CT compared to CT alone in previously untreated patients with 
TNBC (fixed effect: HR= 0.62; CI 95%= 0.51-0.75; p< 0.00001). The PFS was also higher 
in one study with Bev plus CT in previously treated patients (fixed effect: HR= 0.49; 
CI 95%= 0.33-0.74; p= 0.0006). Sor plus CT was available in first-line and second-line. 
The PFS was higher in the group with Sor versus CT alone (fixed effect: HR= 0.69; CI 
95%= 0.49-0.98; p= 0.04) and iniparib plus CT (fixed effect: HR= 0.75; CI 95%= 0.62-0.90; 
p= 0.002). ConClusions: Bev, Sor and iniparib, when associated with the conven-
tional CT, demonstrated gains in the PFS of patients with TNBC.
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objeCtives: Abiraterone and enzalutamide are two new treatment options for 
patients with mCRPC after docetaxel-based chemotherapy. This study aims to 
understand the relative clinical and economic value of these therapies. Methods: 
Two pivotal clinical trials were conducted to evaluate abiraterone and enzalutamide 
in post-docetaxel treatment of mCRPC: Study COU-AA-301 for abiraterone and the 
AFFIRM trial for enzalutamide. The PICO (population, intervention, comparison, and 
outcomes) construct was employed to assess the comparability of the trials, followed 
by an indirect treatment comparison (ITC) using the Bucher method and a mix treat-
ment comparison using Bayesian statistics. An economic evaluation was performed 
based on the ITC results. Results: Several key differences were identified between 
the COU-AA-301 and AFFIRM trials. First, the studies used different comparators. 
Abiraterone plus prednisone was compared with prednisone alone, while enzaluta-
mide was compared with placebo. Second, the endpoints rPFS, PSA progression, and 
PSA response were defined differently between trials, and thus were not included in 
the analysis. To address the difference in comparators, the ITC was performed using 
data from COU-AA-301 and subjects receiving corticosteroids concurrently in the 
AFFIRM trial. OS was significantly improved with both abiraterone and enzalutamide 
(3.9 and 3.2 months respectively). The ITC results were HR = 0.949 (95% CI: 0.712-1.26) 
for abiraterone versus enzalutamide using the Bucher method, and HR = 0.948 (95% CI: 
0.711-1.26) using the Bayesian method. Using the US price for abiraterone and enza-
lutamide (approved in the US only), and assuming 25% of patients received therapy 
following docetaxel, cost savings from using abiraterone would be > $10K/patient/
